New-Generation Drug-Eluting Stents: Focus on Xience V® Everolimus-Eluting Stent and Resolute® Zotarolimus-Eluting Stent

被引：6
|
作者：
Van Dyck, Christophe J. [1 ,2 ]
Hoymans, Vicky Y. [1 ,2 ]
Haine, Steven [1 ,2 ]
Vrints, Christiaan J. [1 ,2 ]
机构：
[1] Univ Antwerp Hosp, Dept Cardiol, Lab Cellular & Mol Cardiol, B-2650 Antwerp, Belgium
[2] Univ Antwerp, Dept Translat Pathophysiol Res, B-2020 Antwerp, Belgium
来源：
JOURNAL OF INTERVENTIONAL CARDIOLOGY | 2013年 / 26卷 / 03期
关键词：
RANDOMIZED CONTROLLED-TRIAL; CORONARY-ARTERY-DISEASE; CLINICAL FOLLOW-UP; ACUTE MYOCARDIAL-INFARCTION; ONE-YEAR OUTCOMES; ENDEAVOR ZOTAROLIMUS; VASCULAR SCAFFOLD; UNRESTRICTED USE; SPIRIT V; SYSTEM;
D O I：
10.1111/joic.12028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Compared to bare metal stent angioplasty, first-generation drug-eluting stents (DES) have markedly reduced the incidence of in-stent restenosis. However, given the increased concerns over late and very late stent thrombosis, newer-generation DES were developed. To date, these DES have virtually replaced the use of first-generation DES worldwide. In this review article, we carefully consider the pre-clinical and clinical trials that have been performed with currently available, european conformity-marked and Food and Drug Administration-approved new-generation Resolute (R) and Xience V (R) DES. (J Interven Cardiol 2013;26:278-286)
引用
收藏
页码：278 / 286
页数：9
相关论文
共 50 条
  • [21] Predictors of Target Lesion Revascularization about Sirolimus-Eluting Stent, Paclitaxel-Eluting Stent, Zotarolimus-Eluting Stent, and Everolimus-Eluting Stent in Our Single Center
    Takama, Takuro
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (07): : 29S - 29S
  • [22] Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis
    Goel, Sachin
    El-Mallah, Wael
    Ige, Mobolaji
    Gupta, Supriya
    Tuzcu, E. Murat
    Ellis, Stephen
    Kapadia, Samir
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) : B194 - B194
  • [23] Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis
    Almalla, Mohammad
    Schroeder, Joerg
    Pross, Verena
    Marx, Nikolaus
    Hoffmann, Rainer
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2014, 83 (06) : 881 - 887
  • [24] Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF
    van Boven, Nick
    Windecker, Stephan
    Umans, Victor A.
    van Domburg, Ron T.
    Kardys, Isabella
    Akkerhuis, K. Martijn
    van Geuns, Robbert-Jan
    Serruys, Patrick W.
    Magro, Michael
    Raeber, Lorenz
    Boersma, Eric
    [J]. HEART, 2015, 101 (01) : 50 - 57
  • [25] Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis
    Almalla, Mohammad
    Pross, Verena
    Marx, Nikolaus
    Hoffmann, Rainer
    [J]. CORONARY ARTERY DISEASE, 2012, 23 (07) : 492 - 496
  • [26] Performance of the Resolute Zotarolimus-Eluting Stent in Small Vessels
    Caputo, Ronald
    Leon, Martin
    Serruys, Patrick
    Neumann, Franz-Josef
    Yeung, Alan
    Windecker, Stephan
    Belardi, Jorge A.
    Silber, Sigmund
    Meredith, Ian
    Widimsky, Petr
    Saito, Shigeru
    Mauri, Laura
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2014, 84 (01) : 17 - 23
  • [27] Complex Patients Treated With Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents in the Randomized TWENTE Trial: Comparison of 2-Year Clinical Outcome
    Sen, Hanim
    Lam, Ming Kai
    Tandjung, Kenneth
    Lowik, Marije M.
    Stoel, Martin G.
    de Man, Frits H. A. F.
    Louwerenburg, J. W.
    van Houwelingen, Gert K.
    Linssen, Gerard C. M.
    Doggen, Carine J. M.
    Basalus, Mounir W. Z.
    von Birgelen, Clemens
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2015, 85 (01) : 74 - 81
  • [28] Decreased Local Hypercoagulation After Implantation of Everolimus-Eluting and Zotarolimus-Eluting Stents Compared With Early-Generation Drug-Eluting Stents in Patients With Stable Angina
    Yamaguchi, Koji
    Wakatsuki, Tetsuzo
    Ise, Takayuki
    Tobiume, Takeshi
    Yagi, Syusuke
    Iwase, Takashi
    Yamada, Hirotsugu
    Soeki, Takeshi
    Sata, Masataka
    [J]. CIRCULATION, 2013, 128 (22)
  • [29] First-Generation Drug-Eluting Stent Versus Everolimus-Eluting Stents to Coronary Intervention in Dialysis Patients
    Sakakibara, Takashi
    Ishii, Hideki
    Yoneda, Kouhei
    Kawashima, Kazuhiro
    Kawamura, Yoshihiro
    Kamoi, Daisuke
    Aoyama, Toru
    Furuhashi, Kyuuichi
    Kumada, Yoshitake
    Takahashi, Hiroshi
    Tanaka, Miho
    Murohara, Toyoaki
    [J]. CIRCULATION, 2011, 124 (21)
  • [30] Two-Year Clinical Outcome of Patients With Bifurcation Lesions Treated With Second-generation Zotarolimus-Eluting Resolute Stents and Everolimus-Eluting Xience V Stents in the Randomized TWENTE Trial
    Tandjung, Kenneth
    Sen, Hanim
    Lam, Ming Kai
    Lowik, Marije M.
    van Houwelingen, Gert
    Stoel, Martin G.
    Louwerenburg, Hans W.
    de Man, F.
    Linssen, Gerard C.
    Nijhuis, Rogier
    Nienhuis, Mark B.
    von Birgelen, Clemens
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B61 - B61
12345